Market Pulse
Daily · Oct 7, 2026 · data.go.kr + ECOS
KOSPI
6,803.90
-137.49 (-1.98%)
KOSDAQ
898.43
-21.49 (-2.34%)
KOSPI 200
1,073.63
-22.20 (-2.03%)
USD/KRW
1,338.50
207940KOSPI·May 27, 2026
Initiating Coverage: Unwavering Growth, Time to Build Conviction
KB Securities published a company analysis report on Samsung Biologics (207940) titled "Initiating Coverage: Unwavering Growth, Time to Build Conviction".
Summary
Covers Samsung Biologics (207940).
Covered stock
More on 207940
Order concerns ease as growth drivers expandMirae Asset Securities · Jul 27, 2026Fair value of W106trMirae Asset Securities · Nov 24, 2025Spin-off likely to unlock additional valueMirae Asset Securities · Oct 29, 2025Positioning for the next leg of growthMirae Asset Securities · Jul 25, 2025CDMO and biosimilar businesses to be separatedMirae Asset Securities · May 23, 2025Earnings surpass heightened expectationsMirae Asset Securities · Apr 24, 2025Globally leading CDMO in terms of growth and marginsMirae Asset Securities · Jan 23, 2025